applied therapeutics, inc. is a hospital and health care company located in 3104 cherry palm dr, tampa, fl, united states.
Company profile
Ticker
APLT
Exchange
Website
CEO
Shoshana Shendelman
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Applied Therapeutics Inc.
SEC CIK
APLT stock data
Latest filings (excl ownership)
424B3
Prospectus supplement
25 Apr 24
ARS
2023 FY
Annual report to shareholders
22 Apr 24
DEFA14A
Additional proxy soliciting materials
22 Apr 24
DEF 14A
Definitive proxy
22 Apr 24
8-K
Departure of Directors or Certain Officers
15 Apr 24
PRE 14A
Preliminary proxy
11 Apr 24
S-3
Shelf registration
22 Mar 24
D
$100.00 mm in equity / options, sold $100.00 mm, 31 investors
13 Mar 24
8-K
Regulation FD Disclosure
11 Mar 24
10-K
2023 FY
Annual report
6 Mar 24
Latest ownership filings
4
Corwin Dale Hooks
15 Apr 24
3
Corwin Dale Hooks
15 Apr 24
4
Shoshana Shendelman
18 Mar 24
4
Riccardo Perfetti
18 Mar 24
4
Adam Hansard
18 Mar 24
4
Leslie D. Funtleyder
18 Mar 24
4
Constantine Chinoporos
18 Mar 24
3
Constantine Chinoporos
18 Mar 24
SC 13G
JANUS HENDERSON GROUP PLC
8 Mar 24
SC 13D/A
Shendelman Shoshana
5 Mar 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 37.46 mm | 37.46 mm | 37.46 mm | 37.46 mm | 37.46 mm | 37.46 mm |
Cash burn (monthly) | (no burn) | 244.25 k | 5.17 mm | 5.21 mm | 4.91 mm | 4.51 mm |
Cash used (since last report) | n/a | 1.68 mm | 35.53 mm | 35.83 mm | 33.77 mm | 30.99 mm |
Cash remaining | n/a | 35.78 mm | 1.92 mm | 1.62 mm | 3.69 mm | 6.46 mm |
Runway (months of cash) | n/a | 146.5 | 0.4 | 0.3 | 0.8 | 1.4 |
Institutional ownership, Q2 2023
42.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 40 |
Opened positions | 9 |
Closed positions | 5 |
Increased positions | 13 |
Reduced positions | 8 |
13F shares | Current |
---|---|
Total value | 34.97 bn |
Total shares | 48.74 mm |
Total puts | 600.00 |
Total calls | 7.52 mm |
Total put/call ratio | 0.0 |
Largest owners | Shares | Value |
---|---|---|
ARE Alexandria Real Estate Equities | 13.43 mm | $10.88 mm |
BEN Franklin Resources | 7.95 mm | $10.17 bn |
Venrock Healthcare Capital Partners III | 5.80 mm | $8.81 mm |
VR Adviser | 5.66 mm | $7.24 bn |
Alyeska Investment | 4.43 mm | $5.67 bn |
FMR | 2.64 mm | $3.38 bn |
Simplify Asset Management | 2.38 mm | $3.05 bn |
Shendelman Shoshana | 1.49 mm | $806.00 k |
Vanguard | 997.00 k | $1.28 bn |
Rock Springs Capital Management | 780.79 k | $999.41 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
12 Apr 24 | Corwin Dale Hooks | Common Stock | Grant | Acquire A | No | No | 0 | 300,000 | 0.00 | 300,000 |
14 Mar 24 | Adam Hansard | Common Stock | Sell | Dispose S | No | No | 5.39 | 48,871 | 263.41 k | 732,919 |
14 Mar 24 | Funtleyder Leslie D. | Common Stock | Sell | Dispose S | No | No | 5.39 | 28,727 | 154.84 k | 308,421 |
14 Mar 24 | Riccardo Perfetti | Common Stock | Sell | Dispose S | No | No | 5.39 | 110,804 | 597.23 k | 1,031,537 |
News
RBC Capital Reiterates Outperform on Applied Therapeutics, Maintains $12 Price Target
11 Apr 24
FDA Presses Delay Button For Applied Therapeutics' First Potential Marketed Drug For Rare Disease
1 Apr 24
Oxford Industries Posts Weak Results, Joins Applied Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
1 Apr 24
12 Health Care Stocks Moving In Friday's After-Market Session
29 Mar 24
Applied Therapeutics Says FDA Has Extended Review Period For NDA For Govorestat (AT-007) For Treatment Of Classic Galactosemia By Three Months; PDUFA Target Action Date November 28, 2024
28 Mar 24
Press releases
Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024
4 Apr 24
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
28 Mar 24
Applied Therapeutics Announces $100 Million Private Placement
28 Feb 24